{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-269949","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.401222+00:00","generated_at":"2026-05-29T09:42:36.691039+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Forte Biosciences hosts R&D Day focusing on FB102 autoimmune updates","bullets":["R&D Day held December 3, 2024 highlighting FB102 development in autoimmune indications.","Slide deck (Ex-99.1) and updated corporate presentation (Ex-99.2) furnished with the filing.","No specific clinical data or financial guidance disclosed in the 8-K or exhibits."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-269949","json":"https://secwatch.observer/filing/0001193125-24-269949.json","markdown":"https://secwatch.observer/filing/0001193125-24-269949.md","text":"https://secwatch.observer/filing/0001193125-24-269949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524269949/0001193125-24-269949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524269949/d850569d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:42:36.691039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}